Article
27 Mar 2026
FDA Announces Public Hearing And Opportunity To Comment On National Priority Voucher Pilot Program
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
25 Mar 2026
FDA And NIH Take Actions To Reduce Reliance On Animal Testing With New Draft Guidance And Funding Announcement
Article
19 Mar 2026
Q&A: FDA Seeks To Clarify '3-Year Exclusivity' With New Guidance
Article
03 Mar 2026
HHS Kicks Off Rare Disease Week With FDA Release Of Draft Guidance On Plausible Mechanism Framework For Individualized Therapies
Article
24 Feb 2026
Congress Rallies To Extend Rare Pediatric Disease Priority Review Voucher Program
Article
10 Feb 2026
PBM Reform Picks Up Pace With Enactment Of Consolidated Appropriations Act, PBM Fee Disclosure Proposed Rule
Article
09 Jan 2026
CMS Launches Five New Models At The End Of 2025: Looks To Advance ACCESS, BALANCE, MAHA ELEVATE, GLOBE And GUARD In 2026
Article
09 Jan 2026
FDA Issues Key Guidance Updates For Digital Health And Wellness
Article
19 Dec 2025
FDA's TEMPO Pilot Seeks To Expand Access To Chronic Disease Technologies In CMS Collaboration
Article
21 Nov 2025
An Overview Of The Over-the-Counter Monograph Drug User Fee Amendments (OMUFA): Policy Areas To Watch
Article
10 Nov 2025
FDA Issues Draft Guidance With Updated Recommendations For Assessing The Need For Comparative Efficacy Studies In Biosimilar Development
Article
29 Oct 2025
FDA Presses Forward On Patient-Focused Drug Development, Releases Final Guidance Focused On Fit-For-Purpose Clinical Outcome Assessments
Article
24 Oct 2025
FDA Names The First Nine National Priority Voucher Recipients
Article
13 Oct 2025
FDA Continues Focus On AI Fronts, Seeks Public Comment On Measuring And Evaluating AI-enabled Medical Device Performance In The Real-World
Article
06 Oct 2025
The Trump Administration Continues To Make Drug Pricing Moves, Announces First MFN Agreement
Article
01 Oct 2025
FDA Presses Forward On PDUFA VII CGT Commitments With Release Of Draft Guidance On Clinical Trial Design, Methods For Capturing Postapproval Data
Article
29 Sep 2025
FDA's Latest On Emergency Diagnostics And A No-Frills Rescission Of The LDT Rule
Article
25 Sep 2025
FDA Puts Orange B On The Chopping Block
Article
16 Sep 2025
From Foods To Pharmaceuticals, MAHA Strategy Offers Broad Menu Of FDA Actions
Article
10 Sep 2025
FDA Continues Focus On Rare Disease Drug Development, Announces Evidence Principles